Interception of inter-cell communication to advance precision & personalized medicine
Empowering precision immunotherapy through blood-based diagnostics that decode immune signals and guide treatment with unmatched clarity, speed, and scalability.
At EVIIVE, we are on a mission to transform the treatment selection of cancer through our innovative extracellular vesicle biomarker discovery platforms, IMPASS & IMPACT.
Driving next-generation companion diagnostics backed by scientific and clinical experts
Current landscape
Most patients receive first-line IO treatment without knowing if it will work—wasting time, money, and precious response windows.
70%
Around 70% of patients do not respond to first-line IO treatment (> 6 million worldwide per year)
90%
More than 90% non-responders irreversibly progress (e.g. metastasis, resistance, <6 months survival)
60%
More than 60% of Phase III IO trials fail due to poor stratification
60%
Around 60% accuracy in predicting IO response using existing biomarkers & technologies
Source: Cell, Journal for immunotherapy of cancer, Journal of Pathology and National Library of Medicine
Liquid biopsies EV – the untapped communication system between host immune system and tumor environment.
Why EVIIVE
“Most current biomarkers rely on indirect signals. We’re working with something more immediate—extracellular vesicles—as a way to observe biology closer to how it actually behaves.”
Eviive’s EV biomarker technology empowers precise IO treatment at the right time for every patient with an improved prediction power and the potential to make a clinically meaningful difference for patients with cancer.
